Pakistan Stock Exchange Ltd · PSX:PSX
Pakistan Stock Exchange — Sanofi-Aventis Pakistan — Corporate Analyst Briefing 2020
19 slides from Pakistan Stock Exchange's conference presentation, Oct 20, 2020
Slide 1: Corporate Analyst Briefing 2020
©Cultura RM Exclusive/Edwin Jimenez/GettyImages Corporate Analyst Briefing 2020 October 20, 2020 | Karachi
Slide 2: At Sanofi, our passion is to prevent, treat and cure illness
At Sanofi, our passion is to prevent, treat and cure illness and disease throughout life. We are driven to improve the health of communities and to find new solutions for patients by combining breakthrough science with advanced technology. Inspired by the resilience of our patients and strengthened
Slide 3: Sanofi Global Sales 2019
Sanofi Global Sales 2019 BUSINESS NET INCOME COMPANY SALES €7.5bn €36.1bn BUSINESS EARNINGS PER SHARE +2.8% €5.7bn VACCINES €9.2bn €5.99 SPECIALITY CARE €4.7bn All growth rates at constant exchange rates CONSUMER €9.1bn €7.4bn HEALTHCARE +6.4% ORGANIZATION BY GLOBAL BUSINESS UNIT (GBU). In 2019, our
Slide 4: Play to Win Strategy
Play to Win Strategy In December 2019, CEO Paul Hudson unveiled the company’s new strategic framework, Play to Win, to drive growth and unleash fresh inspiration across all Sanofi’s activities. A STRATEGY BASED ON FOUR KEY PRIORITIES Focus on growth Lead with innovation Accelerate efficiency Reinven
Slide 5: Global Business Unit (GBU) organization
Global Business Unit (GBU) organization 3 CORE GBUs FOCUSED ON PRIORITIZED PORTFOLIO STANDALONE GBU Specialty Care General Medicines Vaccines Consumer Healthcare Immunology Diabetes Influenza vaccines Allergy, Cough & Cold Rare Diseases / Cardiovascular Polio Pertussis & Hib, Pain Ra
Slide 6: Sanofi committed to the fight against COVID-19
Sanofi committed to the fight against COVID-19 Securing business Developing Supporting patients, continuity, manufacturing complementary vaccine Investigating treatments healthcare workers and and delivery of medicines approaches and diagnostic solutions health authorities and vaccines Collaborati
Slide 7: Pakistan Pharmaceutical Market
Pakistan Pharmaceutical Market
Slide 8: Total Market PKR 444.2 Billion Gr. 11.1%
Total Market PKR 444.2 Billion Gr. 11.1% BPKR 500 CORP MS Growth CAGR National MNC 450 11.1% MNCs 24 29.6% 11.3% 9.2% 13.9% 400 132 12.3% 29.6% NCs 587 70.4% 11.0% 12.4% 350 118 8.4% 29.6% 300 106 Total 30.3% 611 100.0% 11.1% 11.4% 99 Market 250 93 31.7% 32.1% 200 2020 313 150 281 70.4% 245 70.4% 19
Slide 9: Top 20 MNCs - MAT Q2 2020
VALUE: Rs Mn Only “8” MNCs out of 20 are growing with double digit, In Q2°20 “8” companies have higher growth than the Total MNCs growth. Top 20 MNCs — MAT Q2 - 2020 Basis Next 10 MNCs 15,318 13,022 isha 7,806 7,121 =~ m@uTRICIA 130 RDISK 5,473 5 @ a 3 10,799 PFIZER 10,518 1703. afcerm 103 5,193 Top
Slide 10: Sanofi-Aventis Pakistan Limited
Sanofi-Aventis Pakistan Limited Sanofi-Aventis Pakistan Limited
Slide 11: Financials June 2020
Financials June 2020
Slide 12: Net Sales YTD June 2020
Net Sales YTD June 2020 M PKR Net Company - Sales Net Sales – Net Sales - CHC Net sales – Vaccines 8,000 General Medicines 6.2% decline over last year 19.5% decline over last year 8.7% decline over last 7,000 year 6,000 5,000 6,100 969 5,567 909 174 4,000 7,243 17.1% 6,616 10.8% 140 3,000 2,000 1,00
Slide 13: Net Sales contribution by Business Units – YTD June 2020
Net Sales contribution by Business Units – YTD June 2020 CHC 14% Vaccines 2% 17.1% 10.8% General Medicines xxx M 105 M 84% 12
Slide 14: Key Highlights – Top product sales – YTD June 2020
Key Highlights –Top 10 product sales – YTD June 2020 Others, 29% Flagyl, 20% Sales 1,345 m Clexane, 9% 17.1% 10.8% Phenergan, 3% Sales 572 m Enterogermina, 3% xxx M Amaryl, 9% 105 M Tixylix, 3% Plavix, 4% Claforan, 6% Lantus, 8% Sales 571m No Spa, 6% 13
Slide 15: Key Highlights – YTD June 2020
Key Highlights– YTD June 2020 YTD JUNE 2020 Net Sales Decline in Sales Profit before tax Loss per share (Rs) 6,616 8.7% 14.3 (10.7) Million Million 17.1% 10.8% YTD JUNE 2019 Net Sales Growth in Sales Profit before tax Loss per share (Rs) 7,243 7% 100 (7.31) Million Million 14
Slide 16: Dealing with COVID-19
Dealing with COVID-19
Slide 17: Challenges during COVID-19
Challenges during COVID-19 17.1% 10.8% Sanofi faced disruption in manufacturing and supply of Challenge was to ensure continuity Enable continuity of operations medicines because of the of plant operations and supply of without putting the lives of our unavailability of essential raw quality medicin
Slide 18: Sanofi's response on COVID-19
Sanofi’s response on COVID-19 Management of Business Operations Alternate channels and vendors were explored, where possible, to minimize disruption due to unavailability of API’s due to lock down in Europe. Continuity of Plant Operations and Supplies Arrangements were made to operate plant and supp
Slide 19: Thank You
Thank You
Sanofi-Aventis Pakistan — Corporate Analyst Briefing 2020 on 6ix